{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:45:28Z","timestamp":1794847528313,"version":"4.9.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-generation TKIs (bosutinib, dasatinib and nilotinib) are associated with comparable survival results. The second-generation TKIs may produce earlier deep molecular responses, hence reducing the time to reaching a treatment-free remission (TFR). The choice of the second-generation TKI versus imatinib in frontline therapy is based on the treatment aims (survival, TFR), the CML risk, the drug cost, and the toxicity profile with respect to the patient\u2019s comorbidities. The TKI dosing is more flexible than has been described in the registration trials, and dose adjustments can be considered both in the frontline and later-line settings (e.g., dasatinib 50\u2009mg frontline therapy; dose adjusted schedules of bosutinib and ponatinib), as well as during an ongoing TKI therapy to manage toxicities, before considering changing the TKI. In patients who are not candidates for TFR,\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    (International Scale) transcripts levels &lt;1% are acceptable, result in virtually similar survival as with deeper molecular remissions, and need not warrant a change of TKI. For patients with true resistance to second-generation TKIs or with the T315I gatekeeper mutation, the third-generation TKIs are preferred. Ponatinib should be considered first because of the cumulative experience and results in the CML subsets, including in T315I-mutated CML. A response-based dosing of ponatinib is safe and leads to high TKI compliance. Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib is another potent third-generation TKI with early promising results.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00823-9","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T23:10:44Z","timestamp":1682291444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense"],"prefix":"10.1038","volume":"13","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1618-230X","authenticated-orcid":false,"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","unstructured":"Kantarjian H, Cortes J, Jabbour E & O\u2019Brien S in Mol Hematol. https:\/\/doi.org\/10.1002\/9781119252863.ch6. 2019:71\u201386.","DOI":"10.1002\/9781119252863.ch6"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691\u2013709.","journal-title":"Am J Hematol"},{"key":"823_CR3","unstructured":"Kantarjian H, Jabbour E, Cortes J. in Harrison\u2019s Principles of Internal Medicine, 21e (eds J Loscalzo et al.) (McGraw-Hill Education, 2022)."},{"key":"823_CR4","unstructured":"Sasaki K, Jabbour E, Corte, J, Kantarjian H. in The MD Anderson Manual of Medical Oncology, 4e (eds Hagop M. Kantarjian, Robert A. Wolff, & Alyssa G. Rieber) (McGraw Hill Education, 2022)."},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:1385\u2013415.","journal-title":"J Natl Compr Canc Netw"},{"key":"823_CR7","first-page":"686","volume":"17","author":"M Molica","year":"2019","unstructured":"Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, et al. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019;17:686\u201396.","journal-title":"Clin Adv Hematol Oncol"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","volume":"2","author":"P Jain","year":"2015","unstructured":"Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2:e118\u2013e128.","journal-title":"Lancet Haematol"},{"key":"823_CR9","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"823_CR12","doi-asserted-by":"publisher","unstructured":"Breccia M Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached. eClinicalMedicine.2020;19. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100277.","DOI":"10.1016\/j.eclinm.2020.100277"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/bjh.17989","volume":"196","author":"CCHM Maas","year":"2022","unstructured":"Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE, et al. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989\u20132018. British Journal of Haematology. 2022;196:1219\u201324.","journal-title":"British Journal of Haematology"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JOP.2016.019737","volume":"13","author":"CT Chen","year":"2017","unstructured":"Chen CT, Kesselheim AS. Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing. Journal of Oncology Practice. 2017;13:352\u20135.","journal-title":"Journal of Oncology Practice"},{"key":"823_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1377\/hlthaff.2017.1684","volume":"37","author":"AL Cole","year":"2018","unstructured":"Cole AL, Dusetzina SB. Generic Price Competition For Specialty Drugs: Too Little, Too Late. Health Affairs. 2018;37:738\u201342.","journal-title":"Health Affairs"},{"key":"823_CR16","doi-asserted-by":"publisher","unstructured":"Jenei K, Lythgoe MP & Prasad V CostPlus and implications for generic imatinib. Lancet Regional Health \u2013 Americas. 2022;13. https:\/\/doi.org\/10.1016\/j.lana.2022.100317.","DOI":"10.1016\/j.lana.2022.100317"},{"key":"823_CR17","doi-asserted-by":"publisher","first-page":"e854","DOI":"10.1016\/S2352-3026(22)00246-0","volume":"9","author":"H Kantarjian","year":"2022","unstructured":"Kantarjian H, Pau S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. The Lancet Haematology. 2022;9:e854\u2013e861.","journal-title":"The Lancet Haematology"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia.","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","journal-title":"Blood"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.mayocp.2015.01.014","volume":"90","author":"H Kantarjian","year":"2015","unstructured":"Kantarjian H, Rajkumar SV. Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? Mayo Clinic Proceedings. 2015;90:500\u20134.","journal-title":"Mayo Clinic Proceedings"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1200\/JOP.2013.001351","volume":"10","author":"H Kantarjian","year":"2014","unstructured":"Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10:e208\u2013211.","journal-title":"J Oncol Pract"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaoncol.2019.6390","volume":"6","author":"KM Kenzik","year":"2020","unstructured":"Kenzik KM, Bhatia R, Bhatia S. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status. JAMA Oncol. 2020;6:542\u20136.","journal-title":"JAMA Oncol"},{"key":"823_CR22","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.31852","volume":"125","author":"KM Kenzik","year":"2019","unstructured":"Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among benefiiaries diagnosed with chronic myelogenous leukemia. Cancer. 2019;125:2570\u20138.","journal-title":"Cancer"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"e1811","DOI":"10.1200\/OP.20.00967","volume":"17","author":"B Talon","year":"2021","unstructured":"Talon B, Calip GS, Lee TA, Sharp LK, Patel P, Touchette DR. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. JCO Oncol Practice. 2021;17:e1811\u2013e1820.","journal-title":"JCO Oncol Practice"},{"key":"823_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"823_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic. Leukemia. Blood. 1984;63:789\u201399.","journal-title":"eukemia. Blood"},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1179\/1607845412Y.0000000071","volume":"18","author":"B Uz","year":"2013","unstructured":"Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, et al. EUTOS CML prognostic scoring system predicts ELN-based \u2018event-free survival\u2019 better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18:247\u201352.","journal-title":"Hematology"},{"key":"823_CR27","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","volume":"34","author":"M Pfirrmann","year":"2020","unstructured":"Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138\u201349.","journal-title":"Leukemia"},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11899-022-00668-2","volume":"17","author":"NH Shahrin","year":"2022","unstructured":"Shahrin NH, Wadham C, Branford S. Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication. Curr Hematol Malig Rep. 2022;17:171\u201380.","journal-title":"Curr Hematol Malig Rep"},{"key":"823_CR29","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","volume":"27","author":"WW Zhang","year":"2009","unstructured":"Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, et al. Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance. J Clin Oncol. 2009;27:3642\u20139.","journal-title":"J Clin Oncol"},{"key":"823_CR30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1182\/blood-2022-167764","volume":"140","author":"G Gener-Ricos","year":"2022","unstructured":"Gener-Ricos G, Haddad F, Sasaki K, Issa GC, Skinner J, Takahashi K, et al. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood. 2022;140:1493\u20134.","journal-title":"Blood"},{"key":"823_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126:67\u201375.","journal-title":"Cancer"},{"key":"823_CR32","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"823_CR33","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981\u20137.","journal-title":"Blood"},{"key":"823_CR34","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"JP Radich","year":"2017","unstructured":"Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"823_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61:650\u20139.","journal-title":"Leuk Lymphoma"},{"key":"823_CR36","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","volume":"107","author":"G Gugliotta","year":"2022","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D\u2019Adda M, et al. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. Haematologica. 2022;107:2356\u201364.","journal-title":"Haematologica"},{"key":"823_CR37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35:1344\u201355.","journal-title":"Leukemia"},{"key":"823_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ajh.26550","volume":"97","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022;97:856\u201364.","journal-title":"Am J Hematol"},{"key":"823_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","volume":"7","author":"E Atallah","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, et al. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncology. 2021;7:42\u201350.","journal-title":"JAMA Oncology"},{"key":"823_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232\u20138.","journal-title":"J Clin Oncol"},{"key":"823_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353\u201360.","journal-title":"Blood"},{"key":"823_CR42","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","volume":"98","author":"A Nazha","year":"2013","unstructured":"Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013;98:1686\u20138.","journal-title":"Haematologica"},{"key":"823_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2018.1.168","volume":"2018","author":"N Shanmuganathan","year":"2018","unstructured":"Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematology. 2018;2018:168\u201376.","journal-title":"Hematology"},{"key":"823_CR44","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, et al. Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033\u201341.","journal-title":"Cancer"},{"key":"823_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clml.2021.07.001","volume":"22","author":"J Shaya","year":"2022","unstructured":"Shaya J, Pettit K, Kandarpa M, Bixby D, Mercer J, Talpaz M. Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leukemia. 2022;22:17\u201323.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"823_CR46","doi-asserted-by":"publisher","unstructured":"Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H Chronic myeloid leukemia without major molecular response after 2\u2009years of treatment with tyrosine kinase inhibitor. Am J Hematol. n\/a, https:\/\/doi.org\/10.1002\/ajh.26836.","DOI":"10.1002\/ajh.26836"},{"key":"823_CR47","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/leu.2017.247","volume":"31","author":"TP Hughes","year":"2017","unstructured":"Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529\u201331.","journal-title":"Leukemia"},{"key":"823_CR48","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"key":"823_CR49","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020;37:530\u201342.","journal-title":"Cancer Cell"},{"key":"823_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L, Megan Cornelison A, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87:687\u201391.","journal-title":"Am J Hematol."},{"key":"823_CR51","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"823_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","volume":"94","author":"R Hehlmann","year":"2019","unstructured":"Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94:46\u201354.","journal-title":"Am J Hematol"},{"key":"823_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","volume":"37","author":"HJ Henk","year":"2015","unstructured":"Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37:124\u20133.","journal-title":"Clin Ther"},{"key":"823_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11899-019-00524-w","volume":"14","author":"M Copland","year":"2019","unstructured":"Copland M. Is There a Role for Dose Modification of TKI Therapy in CML. Curr Hematol Malig Rep. 2019;14:337\u201345.","journal-title":"Curr Hematol Malig Rep"},{"key":"823_CR55","doi-asserted-by":"publisher","first-page":"100968.","DOI":"10.1016\/j.blre.2022.100968","volume":"56","author":"JH Lipton","year":"2022","unstructured":"Lipton JH, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Garcia-Guti\u00e9rrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968.","journal-title":"Blood Rev"},{"key":"823_CR56","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","volume":"1","author":"LC Fox","year":"2017","unstructured":"Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 2017;1:802\u201311.","journal-title":"Blood Adv"},{"key":"823_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Br\u00fcmmendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309\u201318.","journal-title":"Blood"},{"key":"823_CR58","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/annonc\/mdy019","volume":"29","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Gambacorti-Passerini C, Br\u00fcmmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29:578\u201387.","journal-title":"Ann Oncol"},{"key":"823_CR59","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00432-017-2402-x","volume":"143","author":"FJ Giles","year":"2017","unstructured":"Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017;143:1585\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"key":"823_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17512433.2021.1894129","volume":"14","author":"Z Wang","year":"2021","unstructured":"Wang Z, Jiang L, Yan H, Xu Z, Luo P. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Exp Rev Clin Pharmacol. 2021;14:445\u201356","journal-title":"Exp Rev Clin Pharmacol"},{"key":"823_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0253-7613.62407","volume":"42","author":"MR Varma","year":"2010","unstructured":"Varma MR, Mathew S, Krishnadas D, Vinayakumar KR. Imatinib-induced pancreatitis. Ind J Pharmacol. 2010;42:50\u201352.","journal-title":"Ind J Pharmacol"},{"key":"823_CR62","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3324\/haematol.2009.010496","volume":"94","author":"F Palandri","year":"2009","unstructured":"Palandri F, Castagnetti F, Soverini S, Poerio A, Gugliotta G, Luatti S, et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica. 2009;94:1758\u201361.","journal-title":"Haematologica"},{"key":"823_CR63","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"823_CR64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"823_CR65","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350.","journal-title":"Blood"},{"key":"823_CR66","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","volume":"4","author":"O Chan","year":"2020","unstructured":"Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020;4:530\u20138.","journal-title":"Blood Adv"},{"key":"823_CR67","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/blood-2021-146175","volume":"138","author":"EJ Jabbour","year":"2021","unstructured":"Jabbour EJ, Deininger MW, Abruzzese E, Apperley JF, Cortes JE, Chuah C, et al. Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. Blood. 2021;138:2550\u20132550.","journal-title":"Blood"},{"key":"823_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-015-0008-5","volume":"1","author":"O Pasvolsky","year":"2015","unstructured":"Pasvolsky O, Leader A, Lakobishvili Z, Wasserstrum Y, Kornowski R, Raanani P. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncol. 2015;1:5.","journal-title":"Cardio-Oncol"},{"key":"823_CR69","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507\u201312.","journal-title":"Blood"},{"key":"823_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/10428194.2020.1855340","volume":"62","author":"EJ Chow","year":"2021","unstructured":"Chow EJ, Doody DR, Wilkes JJ, Becker LK, Chennupati S, Morin PE, et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021;62:1203\u201310.","journal-title":"Leuk Lymphoma"},{"key":"823_CR71","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","volume":"7","author":"A Zulbaran-Rojas","year":"2018","unstructured":"Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018;7:5457\u201369.","journal-title":"Cancer Med"},{"key":"823_CR72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.HS9.0000843528.26169.66","volume":"6","author":"L Busque","year":"2022","unstructured":"Busque L, Harnois M, Szuber N, Delage R, Mollica L, Olney H, et al. S159: QU\u00c9BEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT. HemaSphere. 2022;6:60\u201361.","journal-title":"HemaSphere"},{"key":"823_CR73","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","volume":"22","author":"JR Sachs","year":"2016","unstructured":"Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. Clin Cancer Res. 2016;22:1318\u201324.","journal-title":"Clin Cancer Res"},{"key":"823_CR74","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3324\/haematol.2022.280637","volume":"107","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu Z, Zou J, Wang D, He W, Meng L, et al. Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China. Haematologica. 2022;107:1966\u201370.","journal-title":"Haematologica"},{"key":"823_CR75","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","volume":"193","author":"S Claudiani","year":"2021","unstructured":"Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193:346\u201355.","journal-title":"Br J Haematol"},{"key":"823_CR76","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u2013e383.","journal-title":"Lancet Haematol"},{"key":"823_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07782-z","volume":"21","author":"J Fraisse","year":"2021","unstructured":"Fraisse J, Dinart D, Tos D, Bellera C, Mollevi C. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer. 2021;21:60.","journal-title":"BMC Cancer"},{"key":"823_CR78","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3324\/haematol.2018.214445","volume":"104","author":"G Saglio","year":"2019","unstructured":"Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? Haematologica. 2019;104:862\u20134.","journal-title":"Haematologica"},{"key":"823_CR79","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/jcm10030515","volume":"10","author":"A Iurlo","year":"2021","unstructured":"Iurlo A, Cattaneo D, Bucelli C, Breccia M. Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. J Clin Med. 2021;10:515.","journal-title":"J Clin Med"},{"key":"823_CR80","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/ajh.26686","volume":"97","author":"HM Kantarjian","year":"2022","unstructured":"Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, et al. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022;97:1419\u201326.","journal-title":"Am J Hematol"},{"key":"823_CR81","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50\u2009mg\/day versus standard-dose dasatinib 100\u2009mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97:1413\u20138.","journal-title":"Am J Hematol"},{"key":"823_CR82","doi-asserted-by":"publisher","first-page":"106690.","DOI":"10.1016\/j.leukres.2021.106690","volume":"111","author":"V Kota","year":"2021","unstructured":"Kota V, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2012positive leukemias. Leuk Res. 2021;111:106690.","journal-title":"Leuk Res"},{"key":"823_CR83","doi-asserted-by":"publisher","first-page":"143.","DOI":"10.1186\/s13045-018-0685-2","volume":"11","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11:143.","journal-title":"J Hematol Oncol"},{"key":"823_CR84","first-page":"318.","volume":"130","author":"D Rea","year":"2017","unstructured":"Rea D, Cayuela J-M, Dulucq S, Etienne G. Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED). Blood. 2017;130:318.","journal-title":"Blood"},{"key":"823_CR85","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1182\/blood-2022-157700","volume":"140","author":"F Stagno","year":"2022","unstructured":"Stagno F, Abruzzese E, Iurlo A, Pane F, Attolico I, Sportoletti P, et al. Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study. Blood. 2022;140:9614\u20136.","journal-title":"Blood"},{"key":"823_CR86","unstructured":"US, F. D. A. FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia."},{"key":"823_CR87","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"823_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00420-8","volume":"11","author":"V Garcia-Guti\u00e9rrez","year":"2021","unstructured":"Garcia-Guti\u00e9rrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer Journal. 2021;11:16.","journal-title":"Blood Cancer Journal"},{"key":"823_CR89","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.2021014689","volume":"139","author":"DT Yeung","year":"2022","unstructured":"Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022;139:3474\u20139.","journal-title":"Blood"},{"key":"823_CR90","doi-asserted-by":"crossref","unstructured":"Hughes T, Cortes JE, Rea D, Mauro MJ, Hochhaus A, Kim DW, et al. P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL. HemaSphere.2020;6:599\u2212600.","DOI":"10.1097\/01.HS9.0000845700.84142.c0"},{"key":"823_CR91","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1182\/blood-2022-162249","volume":"140","author":"T Hughes","year":"2022","unstructured":"Hughes T, Cortes JE, Takahashi N, Larson RA, Issa CG, Bombaci F. et al.ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP).Blood. 2022;140:6767\u20138.","journal-title":"Blood"},{"key":"823_CR92","doi-asserted-by":"publisher","first-page":"1700217.","DOI":"10.1183\/13993003.00217-2017","volume":"50","author":"J Weatherald","year":"2017","unstructured":"Weatherald J, Chaumais MC, Savale L, Ja\u00efs X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Resp J. 2017;50:1700217.","journal-title":"Eur Resp J"},{"key":"823_CR93","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bcp.13508","volume":"84","author":"N \u00d6zg\u00fcr Yurtta\u015f","year":"2018","unstructured":"\u00d6zg\u00fcr Yurtta\u015f N, E\u015fkazan AE. Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol. 2018;84:835\u201345.","journal-title":"Br J Clin Pharmacol"},{"key":"823_CR94","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, et al. Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia"},{"key":"823_CR95","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"823_CR96","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","volume":"39","author":"JH Lipton","year":"2015","unstructured":"Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leukemia Res. 2015;39:58\u201364.","journal-title":"Leukemia Res"},{"key":"823_CR97","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/asheducation-2018.1.177","volume":"2018","author":"CF Craddock","year":"2018","unstructured":"Craddock CF. We do still transplant CML, don\u2019t we? Hematology. 2018;2018:177\u201384.","journal-title":"Hematology"},{"key":"823_CR98","doi-asserted-by":"publisher","unstructured":"Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol n\/a https:\/\/doi.org\/10.1002\/ajh.26764.","DOI":"10.1002\/ajh.26764"},{"key":"823_CR99","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ajh.26790","volume":"98","author":"J Radich","year":"2023","unstructured":"Radich J. Allogeneic transplantation for chronic myeloid leukemia: I\u2019m not dead yet. Am J Hematol. 2023;98:4\u20135.","journal-title":"Am J Hematol"},{"key":"823_CR100","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","volume":"11","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM, O\u2019Brien SM, Keating M, Beran M, Estey E, Giralt S, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617\u201320.","journal-title":"Leukemia"},{"key":"823_CR101","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120:2573\u201380.","journal-title":"Blood"},{"key":"823_CR102","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/cncr.29240","volume":"121","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015;121:1637\u201344.","journal-title":"Cancer"},{"key":"823_CR103","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","volume":"70","author":"T Zhou","year":"2007","unstructured":"Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, et al. Crystal Structure of the T315I Mutant of Abl Kinase. Chem Biol Drug Design. 2007;70:171\u201381.","journal-title":"Chem Biol Drug Design"},{"key":"823_CR104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"823_CR105","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in Refractory Philadelphia Chromosome\u2013Positive Leukemias. N Engl J Med. 2012;367:2075\u201388.","journal-title":"N Engl J Med"},{"key":"823_CR106","unstructured":"Food and Drug Administration, U. S. ICLUSIG\u00ae (ponatinib) tablets for oral use (2012). Accessed May 24, 2021. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf."},{"key":"823_CR107","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","volume":"27","author":"ED Pulte","year":"2022","unstructured":"Pulte ED, Chen H, Price LSL, Gudi R, Li H, Okusanya OO, et al. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial. Oncologist. 2022;27:149\u201357.","journal-title":"Oncologist"},{"key":"823_CR108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Res. 2016;48:84\u201391.","journal-title":"Leukemia Res"},{"key":"823_CR109","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/bjh.18359","volume":"198","author":"M Breccia","year":"2022","unstructured":"Breccia M, Olimpieri PP, Celant S, Olimpieri O, Pane F, Iurlo A, et al. Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). Br J Haematol. 2022;198:965\u201373.","journal-title":"Br J Haematol"},{"key":"823_CR110","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ajh.26852","volume":"98","author":"EJ Jabbour","year":"2023","unstructured":"Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM. et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023;98:658\u2013665.","journal-title":"Am J Hematol"},{"key":"823_CR111","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem. 2018;61:8120\u201335.","journal-title":"J Med Chem"},{"key":"823_CR112","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"823_CR113","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.HS9.0000843512.62237.dc","volume":"6","author":"D Rea","year":"2022","unstructured":"Rea D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, et al. S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER \u22652 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE. HemaSphere. 2022;6:56\u201357.","journal-title":"HemaSphere"},{"key":"823_CR114","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Br\u00fcmmendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia"},{"key":"823_CR115","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","volume":"101","author":"A Luna","year":"2022","unstructured":"Luna A, P\u00e9rez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nu\u00f1o C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101:2263\u201370.","journal-title":"Ann Hematol"},{"key":"823_CR116","doi-asserted-by":"crossref","unstructured":"Khadadah F, Turkina AG, Lomaia E, Morozova EV, Shukjov OA, Petrova A, et al. P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY. HemaSphere 2022;6:603\u2013304 (2022).","DOI":"10.1097\/01.HS9.0000845716.75856.2d"},{"key":"823_CR117","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3324\/haematol.2022.281386","volume":"108","author":"CCB Kockerols","year":"2022","unstructured":"Kockerols CCB, Janssen JJWM, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY. et al. Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population. Haematologica. 2022;108:240\u2013244.","journal-title":"Haematologica"},{"key":"823_CR118","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/01.HS9.0000845732.28959.a9","volume":"6","author":"M Breccia","year":"2022","unstructured":"Breccia M, Russo Rossi AV, Martino B, Abruzzese E, Annunziata M, Binotto G, et al. P712: ASCIMINIB ITALIAN MANAGED ACCESS PROGRAM: EFFICACY PROFILE IN HEAVILY PRE-TREATED CML PATIENTS. HemaSphere. 2022;6:607\u20138.","journal-title":"HemaSphere"},{"key":"823_CR119","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1182\/blood-2022-165501","volume":"140","author":"AJ Innes","year":"2022","unstructured":"Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, et al. Real-World Experience of Asciminib: Factors Associated with Response. Blood. 2022;140:6796\u20137.","journal-title":"Blood"},{"key":"823_CR120","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"X Ren","year":"2013","unstructured":"Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, et al. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region\u2013Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. J Med Chem. 2013;56:879\u201394.","journal-title":"J Med Chem"},{"key":"823_CR121","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood-2022-170868","volume":"140","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Zongru L, Qin YZ, Zhao T, Liu B, Chen Z, et al. A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China. Blood. 2022;140:198\u20139.","journal-title":"Blood"},{"key":"823_CR122","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2022-170698","volume":"140","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Hou Y, Hu Y, Li W, Liu X, et al. Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation. Blood. 2022;140:203\u20134.","journal-title":"Blood"},{"key":"823_CR123","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2022-162387","volume":"140","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Koller PB, Oehler VG, Jamy OH, Mukherjee S, Hunter AM, et al. Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood. 2022;140:200\u20132.","journal-title":"Blood"},{"key":"823_CR124","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","volume":"10","author":"FE Nicolini","year":"2010","unstructured":"Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, et al. The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge. Clin Lymphoma Myeloma Leukemia. 2010;10:394\u20139.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"823_CR125","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.clml.2011.03.032","volume":"11","author":"AM Cornelison","year":"2011","unstructured":"Cornelison AM, Welch MA, Koller C, Jabbour E. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation. Clin Lymphoma Myeloma Leuk. 2011;11:S111\u2013113.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"823_CR126","doi-asserted-by":"publisher","first-page":"5179.","DOI":"10.1182\/blood.V122.21.5179.5179","volume":"122","author":"H Johnson-Ansah","year":"2013","unstructured":"Johnson-Ansah H, Naguib D, Mittre H, Kadi S, Troussard XA. T315I Gate Keeper Mutation Responding To Pegylated Interferon Alfa-2a (Peg-IFN) Monotherapy With Major Molecular Response (MMR4) At 12 Months In An Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patient. Blood. 2013;122:5179.","journal-title":"Blood"},{"key":"823_CR127","doi-asserted-by":"publisher","first-page":"e0155959.","DOI":"10.1371\/journal.pone.0155959","volume":"11","author":"V Polivkova","year":"2016","unstructured":"Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, et al. Interferon-\u03b1 Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS ONE. 2016;11:e0155959.","journal-title":"PLoS ONE"},{"key":"823_CR128","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123:2875\u201380.","journal-title":"Cancer"},{"key":"823_CR129","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","volume":"67","author":"M Heiblig","year":"2018","unstructured":"Heiblig M, Rea D, Chr\u00e9tien ML, Charbonnier A, Rousselot P, Coiteux V, et al. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Exp Hematol. 2018;67:41\u201348.","journal-title":"Exp Hematol"},{"key":"823_CR130","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.clml.2018.05.002","volume":"18","author":"A Shacham-Abulafia","year":"2018","unstructured":"Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, et al. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study. Clin Lymphoma Myeloma Leukemia. 2018;18:e295\u2013e301.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"823_CR131","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00277-021-04507-x","volume":"100","author":"T Devos","year":"2021","unstructured":"Devos T, Havelange V, Theunissen K, Meers S, Benghiat FS, Gadisseur A, et al. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry. Ann Hematol. 2021;100:1723\u201332.","journal-title":"Ann Hematol"},{"key":"823_CR132","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clml.2021.11.012","volume":"22","author":"T Sacha","year":"2022","unstructured":"Sacha T, Szczepanek E, Dumnicka P, G\u00f3ra-Tybor J, Niesiob\u0119dzka-Kr\u0119\u017cel J, Prejzner W, et al. The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program. Clin Lymphoma Myeloma Leuk. 2022;22:405\u201315.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"823_CR133","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","volume":"2","author":"P Jain","year":"2015","unstructured":"Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, et al. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015;2:e376\u2013e383.","journal-title":"Lancet Haematol"},{"key":"823_CR134","doi-asserted-by":"publisher","first-page":"113.","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022;15:113.","journal-title":"J Hematol Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00823-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T15:02:25Z","timestamp":1683730945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00823-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00823-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jayastu Senapati -- no conflict of interest. Koji Sasaki -- research funding and honoraria for advisory boards from Novartis. Ghayas Issa-- consulting or advisory role: Novartis, Kura OncologyResearch; research funding: Novartis, Syndax, Kura Oncology. Jeffrey H Lipton\u2014consulting for Bristol Myers Squibb, Novartis, Pfizer, and Takeda; research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda; received honorarium from Bristol Myers Squibb, Pfizer, and Takeda. Jerry Radich -- grants from the National Cancer Institute during the conduct of the study; consulting for Novartis, Bristol Myers Squibb, Takeda, Amgen, Cepheid, Bio-Rad, Adaptive, and SeaGen. Elias Jabbour \u2013 research grants from AbbVie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; consulting fees from AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda. Hagop Kantarjian -- grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz, Novartis, and Pfizer; honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"58"}}